Hide

FDA Advisers Say Yes to Experimental Cancer Therapy

Advisers to the Food and Drug Administration have recommended approval of a new experimental, personalized cancer treatment for children with leukemia. This last-ditch treatment, CAR-T therapy, retrains a patient’s immune system to home in on tumor cells and kill them. This particular treatment, which has the tongue-twisting name tisagenlecleucel, is made by Novartis and it’s one of several being developed by drug companies that want to try to standardize the approach as much as possible so it can be patented and licensed. If the FDA approves t ...